President Donald Trump’s nominee to lead the White House Office of National Drug Control Policy, Sara Carter, said during her Senate confirmation hearing today that cannabis rescheduling is a bipartisan issue. “That would finally at least recognize the medical benefits, but it would allow scientists to study the short- and long-term health impacts,” said Booker. “If confirmed as director, I will comply with all federal laws and fulfill all statutory responsibilities of the ONDCP. However, we will continue to work extensively with research and data. On August 11, President Trump said his administration was considering the issue and that a decision would come “in the next few weeks”.